CHAPEL HILL, N.C., March 17, 2017 /PRNewswire/ -- With the shift toward evidence-based medicine and value-based pricing inthe marketplace, pharmaceutical companies are turning to their Medical Affairs function to create effective guidelines for the dissemination of critical product information to external stakeholders.
And in today's regulatory environment these
To help inform Medical Affairs leaders on this important topic, research and consulting leader Best Practices, LLC conducted benchmarking research to provide a high-level understanding of current organizational policies around data dissemination by field medical staff in North America, Europe, APAC and Emerging Markets. The research found that while no company in the study proactively provides off-label data, 67 percent of companies in United States and 50 percent in Europe reactively provide off-label information.
The report, "Determining Best Practices for Data Dissemination Policies for Global Field Medical Teams," contains reliable industry metrics that will help Medical Affairs leaders better understand how on-label and off-label data discussions are approached by field medical teams at leading biopharmaceutical companies in four major regions across the world.
Topics addressed in this study include:
Best Practices, LLC engaged 18 Medical Affairs leaders at 13 biopharmaceutical companies for this research study.
To access the full report or to download a complimentary summary containing insights found in this report, click on the following link: http://www.best-in-class.com/rr1443.htm.
For related research, visit the Best Practices, LLC Web site at www.best-in-class.com/.
ABOUT BEST PRACTICES, LLC Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmaceutical-data-dissemination-policies-vary-around-the-world-but-off-label-discussions-typically-only-occur-reactively-new-study-finds-300425636.html
SOURCE Best Practices, LLC
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All